R&D channel feed – Endpoints News

R&D channel feed

With PhII success, BridgeBio wades deeper into dwarfism drug debate

3 years ago

Aclaris shares halved after mid-stage skin disorder fail

3 years ago

Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure

3 years ago

Cytokinetics' heart drug shows positive results after FDA rejection of earlier treatment: #ACC23

3 years ago

Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk: #ACC23

3 years ago

Praxis stock tanks after mid-stage movement disorder trial miss

3 years ago

Roche, Exelixis' Tecentriq/Cabometyx combo flunks second PhIII

3 years ago

Intellia gets FDA clearance to start hereditary angioedema gene editing trial in US

3 years ago

MorphoSys chops back again, this time cutting preclinical efforts in late-stage push

3 years ago

Scoop: Ascletis' NASH subsidiary scraps US PhII trial in favor of China

3 years ago

Novo Nordisk touts expansion in Boston, cuts about 100 jobs in two other US cities

3 years ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

3 years ago

Keytruda hits one primary endpoint for use before and after surgery in lung cancer

3 years ago

G1 Therapeutics delays PhIII readout of lead drug — will cut 30% of staff, CFO to exit

3 years ago

Ready to turn a new page, Landos Biopharma offloads former lead program to founder

3 years ago

Pfizer was warned of Lyme study problems months ago, trial research startup's CEO tells employees

3 years ago

Celldex fleshes out case for Xolair challenger in chronic hives

3 years ago

Merck’s Keytruda fails more prostate and lung cancer PhIII trials

3 years ago

Theravance cuts 17% of staff, JAK inhibitor program

3 years ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

3 years ago

Suffering CNS player flips another losing hand in a last PhII gamble and calls for the axe

3 years ago

AstraZeneca expands Canada R&D work, to add 500 jobs

3 years ago

State attorneys general sue FDA over abortion pill access restrictions

3 years ago

Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner

3 years ago

First page Previous page 100 101 102103104 105 106 Next page Last page